FDA Panel Largely Pans Trial Data for Myopia Eye Drops
Summary
(MedPage Today) -- The regulatory status of a low-dose atropine eye drop formulation for myopia remained unresolved following a day-long FDA advisory committee meeting, but closing comments did not bode well for SYD-101. The Dermatologic and Ophthalmic...
Description from Medpagetoday.
Who is covering this
-
FDA Panel Largely Pans Trial Data for Myopia Eye Drops
(MedPage Today) -- The regulatory status of a low-dose atropine eye drop formulation for myopia remained unresolved following a day-long FDA advisory committee meeting, but closing comments did not bode well for SYD-101. The Dermatologic and Ophthalmic...
Related stories
Actor Ajay Devgn moves High Court against FDA notice over Vimal Elaichi ads
7 sourcesvia The HinduTruth score 731
FDA scientists opposed Trump administration’s move to ease peptide access
4 sourcesvia The GuardianTruth score 66
Blood pressure medication recalled nationwide
4 sourcesvia USA TODAYTruth score 671
Patanjali ghee among Rs 9 crore food stock seized in Maharashtra FDA crackdown
3 sourcesvia India TodayTruth score 54
Trump administration says biggest changes coming to infant formula in nearly 30 years
2 sourcesvia ABC News (US)Truth score 533
FDA issues alert about Northfield-based Medline beds tied to fire-related deaths and injuries
3 sourcesvia Chicago Sun-TimesTruth score 59
Comments
Comments need JavaScript.